PF-Atlas › Clinical Trials › NCT01629667

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Tralokinumab · Phase 2

Registry ID

NCT01629667

Phase

Phase 2

Status

Terminated

Drug / intervention

Tralokinumab

Sponsor

MedImmune LLC

Start

2012-10

Enrollment

409

Locations

About this trial

To study the safety and effectiveness of multiple-doses of tralokinumab on pulmonary function in adults with mild to moderate idiopathic pulmonary fibrosis (IPF). IPF is a chronic, progressive, irreversible, and usually fatal lung disease of unknown cause.

View NCT01629667 on ClinicalTrials.gov →

Explore related

All Tralokinumab trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT01629667 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.